Clinical Trial Update: Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating epcoritamab in combination with loncastuximab tesirine for relapsed/refractory diffuse large B-cell lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• EPKINLY (EPCORITAMAB-BYSP)
• Zynlonta (loncastuximab tesirine)

Snippet

Sponsor: University of Miami | Conditions: Large B-cell Lymphoma, Relapse | Phase 2 | Status: RECRUITING